CBIO
Crescent Biopharma, Inc.
NASDAQ · USHealthcareBiotechnology
$15.05+2.03%
Price as of Jul 20, 2026
CBIO valuation
Crescent Biopharma, Inc. valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- -37.49x
Trailing multiples
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.26x
- Price / sales
- 34.92x
- Price / cash flow
- -5.96x
Enterprise value
- Enterprise value
- $231.3M
- EV / sales
- 19.47x
- EV / EBITDA
- -1.46x
- EV / EBIT
- -1.42x
- Market cap
- $415.0M
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.